Upon activation of CLTs and NK cells, the CD95 ligand and TRAIL are de novo synthesized and either expressed on the surface of CTLs and NK cells or released via an exosome-mediated pathway to kill susceptible tumor cells through the interaction of these ligands with their respective death receptors. This evidence concerns the gene TNFSF10 and neoplasm.